智通财经APP获悉，招银国际发布研报称，维持和黄医药(00013)“买入”评级，目标价由35.61港元修订为34.03港元。该行称，和黄医药去年业绩表现强劲，受惠旗下FRUZAQLA(fruquintinib)海外销售强劲，带动营业额增长，肿瘤/免疫产品收入同比增长65%至2.72亿美元，超出之前30至50%增长的指引目标。该行预期FRUZAQLA的海外销售将持续保持强劲势头，对公司2025年3.5亿至4.5亿美元的肿瘤业务目标充满信心，并预计其合并产品组合在2025财政年度的市场销售将同比增长35%。配合公司保守的2025财政年度收入目标，该行亦调整收入预测。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.